I saw a presentation yesterday by Carolyn Compton, the new head of C-PATH, the critical path institute located in Tucson, AZ. This group has the goal of accelerating the development of new medicines by working at the interface between pharmaceutical companies, academic researchers and clinicians, the FDA, and the public.